Litcius/Paper detail

Peripheral Evolution of Tanshinone IIA and Cryptotanshinone for Discovery of a Potent and Specific NLRP3 Inflammasome Inhibitor

Wenqi Zhu, Xiaodong Bao, Yuyan Yang, Ma Xing, Sijie Xiong, Siyu Chen, Yongxin Zhong, Xueping Hu, Q Richard Lu, Kairong Wang, Qi Ling, Sunliang Cui

2025Journal of Medicinal Chemistry8 citationsDOI

Abstract

Natural products (NPs) continue to serve as an invaluable source in drug discovery, and peripheral evolution of NPs is a highly efficient evolution strategy. Herein, we describe a unified “methyl to amide” peripheral evolution of Tanshinone IIA and Cryptotanshinone for discovery of NLRP3 inflammasome inhibitors. There were 54 compounds designed and prepared, while the chemoinformatic analysis revealed that these evolved NP analogues occupy a unique chemical space. Biological evaluation identified 5m as an NLRP3 inflammasome inhibitor, and 5m could directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus suppressing ASC oligomerization and NLRP3 inflammasome assembly. Molecular dynamic stimulations revealed that the amide moiety played a vital role in the binding mode. Moreover, 5m exhibited therapeutical efficacy in sepsis and the NASH mouse model. In conclusion, this protocol provides a new vision of NPs’ peripheral evolution and a novel NLRP3 inflammasome inhibitor.

Topics & Concepts

ChemistryInflammasomePharmacologyPeripheralBiochemistryReceptorInternal medicineMedicineInflammasome and immune disordersGout, Hyperuricemia, Uric AcidNatural product bioactivities and synthesis
Peripheral Evolution of Tanshinone IIA and Cryptotanshinone for Discovery of a Potent and Specific NLRP3 Inflammasome Inhibitor | Litcius